Tarek Samad Takes the Helm as EVP and Leader of Research at Lundbeck

Tarek Samad Takes the Helm at Lundbeck as EVP of Research & Development

In an exciting development within the biopharmaceutical sector, H. Lundbeck A/S has announced the appointment of Tarek Samad as the new Executive Vice President (EVP) and Head of Research & Development (R&D). This strategic move is set to take effect on September 1, 2026, as Samad succeeds Johan Luthman, following his retirement after a commendable tenure of seven years.

Background of the Transition

The transition period begins this July to ensure a smooth handover of responsibilities. Luthman will remain involved until the end of the year to maintain continuity in crucial strategic and scientific endeavors. CEO Charl van Zyl praised Luthman for his tremendous contributions, emphasizing that under his leadership, the R&D organization underwent significant restructuring and a shift in focus that has paved the way for innovative breakthroughs.

Samad, currently serving as Senior Vice President and Global Head of Research and Corporate Patents, has been integral to Lundbeck's R&D strategy since 2021. His leadership in advancing scientific excellence and nurturing high-performing teams is well recognized, and his new position confirms Lundbeck’s commitment to fostering internal talent.

Samad's Impressive Credentials

Before his influential role at Lundbeck, Samad accumulated an impressive track record, having held high-ranking research positions at Immunitas Therapeutics, Sanofi, and Pfizer. His academic credentials include a faculty position at Harvard Medical School and Massachusetts General Hospital. This rich background positions him perfectly to lead Lundbeck’s R&D efforts into their next phase.

In his own words, Samad expressed enthusiasm for his new role: “Lundbeck combines a unique legacy of scientific excellence with an unwavering commitment to advancing innovation and improving the lives of people living with brain diseases.” He underscores the team's dedication to scientific inquiry and their collaborative efforts to enhance treatment options for patients—a mission that aligns with Lundbeck's core focus.

Luthman's Legacy and Achievements

Johan Luthman’s retirement marks the end of an era characterized by transformative change within Lundbeck. His tenure was defined by the establishment of broader drug modality platforms and an expansion into new biological research areas, significantly enhancing the company’s R&D capabilities. Luthman has been credited with launching innovative new medicines and providing robust support for Lundbeck's products in global markets, which has solidified the company’s reputation as a leader in the neuroscience field.

Reflecting on his time at Lundbeck, Luthman stated, “After seven exciting years, I believe this is the right time to transition leadership.” He expressed pride in the progress made under his stewardship and a deep gratitude towards his colleagues for their dedication and hard work—elements that have been critical to these achievements.

Future Outlook for Lundbeck's R&D

As Lundbeck gears up for the future, Tarek Samad’s appointment as EVP of R&D is poised to carry the momentum forward. His strong foundation within the company and commitment to exploring new treatment opportunities are set to advance Lundbeck’s research agenda further. The company’s goal is to address complex neurological challenges and continue to develop transformative medicines for patients worldwide.

This transition signifies Lundbeck’s strategic intent to build upon its legacy while maintaining leadership continuity as it navigates the fast-evolving landscape of brain health. With Samad at the helm, the R&D organization is well-positioned to innovate and deliver new solutions that enhance the lives of those affected by neurological and psychiatric disorders.

Conclusion

The narrative of Tarek Samad stepping into the EVP role at Lundbeck is not merely a change in leadership; it represents a renewed commitment to scientific excellence and innovation in the realm of brain health. As the company moves forward, the continuity of leadership, paired with fresh insights from Samad, promises to keep Lundbeck at the forefront of neuroscience and patient care.